22 results about "Viremia" patented technology

The present application relates to a virus of reverse genetic operation construction of NADC34-like PRRSV2. Specifically, the full gene sequence of NADC34-like PRRSV2 BJ1805-2 isolated strain is segmented and connected to the vector by using PCR amplification, enzyme digestion and other methods with pACY177 plasmid as the carrier, and the BJ1805-2 full-length infectious clone recombinant plasmid (rBJ1805-2) is obtained. The infectious clone virus rBJ1805-2 is rescued in vitro, and the first NADC34-like PRRSV2 strain infectious clone platform in China is successfully built. The present application also relates to a modification method for constructing NADC34-like PRRSV2 strain which can adapt to Marc-145 cell passage culture. The infectious clone virus constructed by the present application has good in vitro and in vivo proliferation efficiency, and can cause specific viremia after inoculation in pigs; it has good safety, does not cause fever after inoculation in pigs, and will not cause piglet death. The modified strain can be used as a candidate strain for developing the first NADC34-like PRRSV2 specific vaccine in China, and is conducive to the prevention and control of PRRSV epidemic in China.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

The invention belongs to the technical field of aquaculture, and relates to a new application of capsaicin, in particular to an application of capsaicin in preparation of drugs and / or feed additives for preventing and treating fish virus infection. The core of the invention lies in that the capsaicin has an obvious protection effect on infection of spring viraemia of carp virus (SVCV), grass carp reovirus (GCRV) and herpesvirus type 2 (CyHV-2), and can obviously inhibit transcription of SVCV, GCRV and CyHV-2 virus genes and expression of virus proteins. The capsaicin-containing feed additive and / or medicine can be used for preventing and treating fish virus diseases, and has the advantages of high protection efficiency and environmental friendliness.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The application relates to the technical field of virus genetic engineering, and particularly relates to a construction method of a porcine respiratory syndrome virus. The construction method is as follows: taking a PRRSV HEB1 strain genome (GenBank EF112447.1) as a template and modifying the same, then cloning the modified genome into a pBAC11 carrier, carrying out in-vitro transcription and transfecting Marc-145 cells, and rescuing a recombinant virus rPRRSV-HA-CMV-mC. The recombinant PRRSV strain shows significant replication delay and titer reduction, forming an attenuated phenotype. Further, the recombinant virus is emulsified with an ISA206 oil adjuvant to prepare a vaccine, which shows high immunogenicity in piglet immunization, can significantly reduce clinical symptoms, viremia and lung pathological damage after PRRSV infection, and has the potential to be developed into a safe and effective vaccine.

The application discloses a chimeric Kunjin virus of tamabi virus prM-E and a preparation method and application thereof. On the basis of a reverse genetic manipulation system of the Kunjin virus KUNV, the KUNV prM / E gene is replaced by the DTMUV prM / E gene to construct a chimeric DTMUV virus infectious clone plasmid with the KUNV as a skeleton, which is named as pUC19-KUNV-DTMUV prM / E. Then, the chimeric tamabi virus prM-E Kunjin virus is obtained through virus rescue, and is named as rKUNV-CHv-prM / E (CHv). Analysis on the virus characteristics shows that the CHv can effectively proliferate in BHK-21 and DEF cells, and the duck embryo virulence is weaker than that of the KUNV and the DTMUV. The animal experiment results show that the CHv only detects obvious virus levels in the brain, and does not produce viremia; the CHv after immunization can produce similar IgG antibody levels to those after immunization of the KUNV and the DTMUV. Therefore, the recombinant virus of the chimeric DTMUV prM / E with the KUNV as a skeleton prepared by the application can induce the duckling to produce sufficient immune protective neutralizing antibody levels, and can be applied to preparation of a duck tamabi virus vaccine.

The application belongs to the technical field of genetic engineering of aquatic animals, and discloses application of fish VDAC2 genes in resisting inflammation reaction induced by aquatic viruses. Experimental data of the application show that the inflammation reaction caused by SVCV can be significantly inhibited by using VDAC2 inhibitor Dids or knocking down VDAC2, and the survival rate of fish after infection with the SVCV virus can be effectively improved, so VDAC2 plays an important role in regulating the inflammation reaction induced by the spring viremia of carp virus. The application provides a new drug target for virus prevention and control in the field of aquatic products, and has important significance for prevention and control of aquatic viruses.

The application provides an application of hepatocyte nuclear factor HNF4beta in preparation of a fish disease preventing and / or treating fish biological product, and belongs to the technical field of biotechnology. Through in-vivo experiments, it is found that overexpression of hepatocyte nuclear factor HNF4beta in a fish body can effectively prevent and / or inhibit pathogenic bacteria, especially Edwardsiella tarda, spring viremia of carp virus (SVCV) and grass carp reovirus (GCRV). Meanwhile, the hepatocyte nuclear factor HNF4beta can effectively regulate the immune system, control the occurrence of hepatobiliary syndrome and significantly improve the survival rate of juvenile fish. In addition, the application first proves that HNF4beta can effectively control the hepatobiliary syndrome induced by GCRV infection. The application provides a molecular target for prevention and control of infectious diseases, metabolic diseases and metabolic disease-induced infectious diseases of the Cyprinidae family.

The present disclosure provides a novel serological method for detecting viremia or a latent human-livestock co-occurrence virus infection (e.g., porcine cytomegalovirus (PCMV) or porcine lymphotropic herpesvirus (PLHV) infection) in a subject at any stage of development. More specifically, the present disclosure provides automated multiplex immunoassays for the rapid and simultaneous detection of one or more anti-PCMV or anti-PLHV antibodies in a biological fluid of a subject suspected of being infected with PCMV or PLHV.

The invention discloses a porcine reproductive and respiratory syndrome virus CD163 key SRCR5 structural domain epitope peptide, an epitope peptide vaccine and application. The epitope vaccine is good in safety, has no safety problems of virulence reversion, generation of viremia, recombination with other PRRSV strains and the like, has good immunogenicity, and can induce a pig to generate a specific antibody aiming at the CD163 SRCR5-FP14 epitope with the highest agglutination titer of 1: 16 14 days after secondary immunization, and the immunized pig can resist attack of a highly pathogenic PRRSV JAX1 strain. Each subtype strain of the PRRSV is dependent on interaction with a CD163 receptor so as to infect a host susceptible cell, and CD163 molecules are conservative, so that the epitope vaccine for blocking PRRSV infection also has a broad-spectrum protection effect on various subtype strains, the production performance of pigs is not influenced, and the novel epitope vaccine has a wide potential application prospect in PRRS prevention and control.

The application discloses a duck Tembusu virus attenuated strain, and a nucleotide sequence of the duck Tembusu virus attenuated strain is shown as SEQ ID NO:1.The duck Tembusu virus attenuated strain can immunize ducklings and make the ducklings produce effective duck Tembusu virus antibodies, the protection rate of the ducklings reaches 100%, meanwhile, the weight growth of the ducklings is not affected, and there is no virus discharge, death and viremia, and the duck Tembusu virus is not detected in main organs of the ducklings.The duck Tembusu virus attenuated strain can also be used as a live vector to embed H5N6 subtype avian influenza virus antigen epitopes, and further construct a live vector vaccine strain, and the live vector vaccine strain can immunize ducklings and effectively reduce the damage of H5N6 subtype avian influenza virus to the ducklings.

The invention provides a double qPCR method, a reagent and a kit for realizing ultra-early diagnosis of African swine fever by jointly detecting nucleic acids of host biomarkers HP and ASFV. According to the present invention, the HP and B646L genes are adopted to establish the dual fluorescence PCR method, the biomarker HP and ASFV nucleic acid detection are innovatively combined for use, the ASFV infection is diagnosed, the potential ASFV early stage infected pigs in the pig farm can be screened, the diagnosis blank period before the occurrence of the viremia after the ASFV infection is filled, and the kit can be used for the diagnosis of the ASFV early stage. Especially, a new technical tool is provided for coping with challenges of African swine fever virus variation and recombinant strains. According to the method, the efficiency of biological safety measures can be improved, the implementation precision of a'detection-killing 'strategy is optimized, the method is suitable for precise removal when ASF epidemic outbreak occurs in a pig farm or ASF epidemic outbreak occurs in the periphery, and an early monitoring and early warning means is provided for epidemic prevention and control.

The invention belongs to the technical field of molecular biology and microbiology, and particularly relates to an antibacterial peptide for resisting spring viremia of carp virus and application thereof, and the antibacterial peptide is any one of the following: 1) an amino acid sequence as shown in SEQ ID NO.1; and 2) a nucleotide sequence for coding the amino acid sequence as shown in SEQ ID NO. 1. The invention reveals that the antibacterial peptide NKLj27 has remarkable anti-SVCV activity for the first time, can effectively inhibit infection of SVCV on EPC cells at the cellular level, and alleviates cytopathy and plaque formation caused by viruses. Meanwhile, the NKLj27 shows a good protection effect on SVCV infection at a carp living body level, the death rate caused by virus infection can be remarkably reduced, and the evidences show that the NKLj27 has remarkable anti-SVCV activity. The invention provides a new candidate drug for prevention and control of fish virus diseases.

The invention relates to the technical field of medical biological detection, provides a novel application of HBV RNA, particularly relates to an application in preparation of an LLV screening kit, and further provides a kit and a detection method for performing LLV screening by quantitative detection of HBV RNA. HBV RNA can reflect cccDNA in the liver of a chronic hepatitis B patient and the level of transcriptional activity of cccDNA. In disease assessment and follow-up visit of chronic hepatitis B patients, as a non-invasive assessment means, serum HBV RNA level dynamic monitoring is helpful for early recognition of potential LLV patients, so that the patients are intervened as soon as possible and disease progression is prevented in clinical diagnosis and treatment of chronic hepatitis B.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method and device for predicting a BK virus infection disease stage based on gene expression. The method comprises the following steps: obtaining a tissue sample of a to-be-tested person; obtaining an expression amount of a target gene of a region of interest based on the tissue sample, the region of interest being PanCK+, and the target gene comprising one or more of the following: HLA-DPA1 and LYZ; inputting the expression amount of the target gene of the region of interest into a classifier, and predicting a BK virus infection stage of the to-be-tested person according to an output of the classifier, wherein the BK virus infection stage comprises the following: non-infection, BK viremia, and BK nephropathy. The application realizes the differentiation of BK virus infection stages based on gene expression, and helps to realize symptomatic treatment from the gene expression level.

The application discloses application of deoxycholic acid in preparation of a medicine or additive for resisting aquatic virus infection, wherein the aquatic virus is a spring viremia of carp virus and / or infectious hematopoietic necrosis virus. Experimental data show that the deoxycholic acid can significantly inhibit the proliferation of the spring viremia of carp virus and the infectious hematopoietic necrosis virus in vivo and in vitro, and effectively improve the survival rate of fish after being infected with the two viruses, so that the deoxycholic acid can be developed as a medicine and a feed additive for preventing and controlling viruses in the field of aquaculture, and has important significance for preventing and controlling aquatic viruses.

The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVAG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVAG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses. Vaccination may occur via intramuscular administration, oral administration, or intranasal administration.

The present application relates to aquatic animal antiviral technology field, especially to a kind of anti-carp edema virus protein of brocade carp and its application.The amino acid sequence of the anti-carp edema virus protein provided in the present application is shown as SEQ ID NO.1, and the 1-27th amino acid of the amino acid sequence is signal peptide.The nucleotide sequence of the brocade carp Viperin gene for encoding the anti-carp edema virus protein is shown as SEQ ID NO.2.Injection of the Viperin recombinant protein obtained in the present application can improve the immune gene expression of brocade carp infected with carp edema virus.Moreover, after injection of the Viperin recombinant protein obtained in the present application, the content of carp edema virus in gill tissue of brocade carp is significantly lower than that of the control group, and the anti-carp edema virus protein provided in the present application has a significant inhibitory effect on brocade carp infected with carp edema virus.

The invention provides an attenuated mutant virus of a high-pathogenicity PRRSV-1 subtype 1 strain with intestinal tropism and application of the attenuated mutant virus, the attenuated mutant strain is named as a PRRSV-1GXFS20220129-P100 strain, the attenuated mutant strain is obtained by continuous passage of the high-pathogenicity PRRSV-1 subtype 1 GXFS20220129 strain with intestinal tropism to the 100th generation (P100) on MARC-145 cells, the attenuated mutant strain is preserved in China Center for Type Culture Collection (CCTCC) on April 29, 2025, and the preservation number is CGMCC NO. The preservation number of the strain is CCTCC (China Center For Type Culture Collection) NO: The strain has high-titer multiplication capacity (the virus titer can reach 107TCID50 / mL or above), high safety and good immunogenicity. The vaccine prepared from the homologous PRRSV-1GXFS20220129 virulent strain has the advantages that the immune efficacy is fast to generate, the immune blank period can be obviously shortened, the infection of the homologous PRRSV-1GXFS20220129 virulent strain can be effectively prevented by one-time immunization, and clinical symptoms and pathological injuries can be obviously alleviated after the virus attack, and the viremia and tissue virus load can be reduced. The strain provides an important candidate strain for developing a safe and effective PRRSV-1 subtype 1 attenuated live vaccine.

The invention relates to the technical field of medical biological detection, provides new application, particularly application in preparation of an LLV screening kit, and further provides a kit and a detection method for performing LLV screening by specific quantitative detection. The cccDNA in the liver of a chronic hepatitis B patient and the level of transcriptional activity of the cccDNA can be In disease assessment and follow-up visit of chronic hepatitis B patients, as a non-invasive assessment means, serum level dynamic monitoring contributes to early recognition of potential LLV patients, so that the patients are intervened as soon as possible and disease progression is prevented in clinical diagnosis and treatment of chronic hepatitis B.